Fasiglifam在2型糖尿病患者中的肝损伤:随机对照心血管结局安全性试验结果
本研究为一项3期多中心随机双盲安慰剂对照试验,计划纳入5000例心血管高风险2型糖尿病患者,评价GPR40激动剂fasiglifam的心血管安全性。实际纳入3207例后因肝脏安全性担忧提前终止。Fasiglifam组肝酶升高发生率显著高于安慰剂组,ALT或AST≥3倍正常上限的发生率为2.1%对0.5%(P<0.001),≥10倍正常上限为0.31%对0.06%(P<0.001)。主要心血管复合终点12个月时两组均为2.5%(HR 1.05;95%CI 0.67,1.63)。
要点
- Fasiglifam导致ALT或AST≥3倍正常上限发生率显著高于安慰剂(2.1%对0.5%,P<0.001)。
- Fasiglifam组ALT或AST≥10倍正常上限发生率为0.31%,安慰剂组为0.06%(P<0.001)。
- 主要心血管复合终点12个月时两组均为2.5%(HR 1.05;95%CI 0.67,1.63)。
核心结论
- Fasiglifam因药物性肝损伤担忧而终止开发,FDA要求的CV结局试验支持终止该临床项目。
研究设计与样本
- 3期多中心随机双盲安慰剂对照两臂试验,计划随机5000例心血管高风险2型糖尿病患者,实际纳入3207例后因肝脏安全性担忧终止。
- 主要目标为排除fasiglifam相比安慰剂心血管复合事件风险比单侧97.5%置信上限>1.3。
- 主要结局为心血管死亡、非致死性心肌梗死、非致死性卒中和不稳定心绞痛住院的复合终点首次发生时间。
主要发现
- Fasiglifam组ALT或AST≥3倍正常上限发生率为2.1%,安慰剂组为0.5%(P<0.001)。
- Fasiglifam组ALT或AST≥10倍正常上限发生率为0.31%,安慰剂组为0.06%(P<0.001)。
- 主要心血管复合终点在12个月时fasiglifam组和安慰剂组均为2.5%(HR 1.05;95%CI 0.67,1.63),共40例发生。
关键数值与推荐
- ALT或AST≥3倍正常上限:fasiglifam组2.1% vs 安慰剂组0.5%,P<0.001。
- ALT或AST≥10倍正常上限:fasiglifam组0.31% vs 安慰剂组0.06%,P<0.001。
- 主要心血管复合终点12个月发生率:两组均为2.5%,HR 1.05(95%CI 0.67,1.63)。
临床怎么用
- Fasiglifam因肝损伤风险已终止开发,临床不应使用该药物。
- GPR40激动剂类药物的研发需重视肝脏安全性监测。
局限性
- 试验因肝脏安全性担忧提前终止,实际样本量(3207例)低于计划(5000例)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cardiovascular (CV) safety of fasiglifam, a first-in-man G-protein-coupled receptor 40 (GPR40) agonist, in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A phase 3 multicenter randomized double-blind placebo-controlled two-arm trial was intended to randomize 5,000 participants with type 2 diabetes at high CV risk to fasiglifam or placebo. The primary objective of the trial was to rule out an upper noninferiority bound >1.3 for a one-sided 97.5% confidence limit of the hazard ratio (HR) for CV composite events during treatment with fasiglifam compared with placebo. The primary outcome was the time to first occurrence of any component of the major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina. RESULTS: The study enrolled 3,207 participants but was terminated because of liver safety concerns. Increased rates of liver enzyme elevation (AST/ALT ≥3-5 × upper limit of normal [ULN]) with fasiglifam were observed. The incidence of ALT or AST ≥3 × ULN with fasiglifam compared with placebo was 2.1% vs. 0.5%, P < 0.001, and the incidence for ≥10 × ULN was 0.31% vs. 0.06%, P < 0.001. A primary CV composite outcome occurred in 40 participants, 2.5% each in the fasiglifam and placebo arms at 12 months (HR 1.05; 95% CI 0.67, 1.63). CONCLUSIONS: Development of fasiglifam was terminated due to concerns of drug-induced liver injury. Performance of a U.S. Food and Drug Administration-mandated CV outcomes trial supported the termination of the fasiglifam clinical program.
引用
- Menon V, Lincoff AM, Nicholls SJ, et al. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. Diabetes Care. 2018. PMID: 30459247. doi:10.2337/dc18-0755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。